We advised Roche on the transaction

Davis Polk advised Roche on its acquisition of SAGA Diagnostics. Roche will pay total consideration of up to $595 million, inclusive of commercial and regulatory milestone payments. Following the transaction, SAGA’s Pathlight molecular residual disease platform will be fully integrated into Foundation Medicine, an independent affiliate of the Roche group.

Founded in Basel, Switzerland in 1896, Roche is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases.

SAGA Diagnostics is a precision diagnostics company focused on molecular residual disease detection and cancer recurrence monitoring. Its Pathlight platform uses a proprietary combination of whole genome sequencing and digital PCR to identify and track structural variants, enabling ultra-sensitive molecular residual disease detection.

The Davis Polk corporate team included partner Brian Wolfe, counsel Joshua B. Pittell and associate Jesse A. Miot. Partner David R. Bauer, counsel Samantha Lefland and associate Daniella Martino provided intellectual property advice. Partner Veronica M. Wissel and counsel Andrew H. Braid provided executive compensation advice. Partner Matthew Yeowart provided antitrust and competition advice. Partner Michael Mollerus provided tax advice. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post